Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 6
1989 3
1990 1
1992 2
1993 1
1994 1
1995 1
1996 2
1997 1
1998 4
1999 2
2000 2
2001 2
2002 3
2003 2
2004 2
2005 2
2006 2
2007 2
2008 2
2009 5
2010 5
2011 10
2012 14
2013 16
2014 15
2015 17
2016 18
2017 16
2018 17
2019 13
2020 9
2021 13
2022 14
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Family planning considerations in people with multiple sclerosis.
Krysko KM, Dobson R, Alroughani R, Amato MP, Bove R, Ciplea AI, Fragoso Y, Houtchens M, Jokubaitis VG, Magyari M, Abdelnasser A, Padma V, Thiel S, Tintore M, Vukusic S, Hellwig K. Krysko KM, et al. Among authors: fragoso y. Lancet Neurol. 2023 Apr;22(4):350-366. doi: 10.1016/S1474-4422(22)00426-4. Lancet Neurol. 2023. PMID: 36931808 Review.
Cannabis and multiple sclerosis.
Fragoso YD, Carra A, Macias MA. Fragoso YD, et al. Expert Rev Neurother. 2020 Aug;20(8):849-854. doi: 10.1080/14737175.2020.1776610. Epub 2020 Jun 18. Expert Rev Neurother. 2020. PMID: 32515670 Review.
Age-friendly city: future perspectives for the Brazilian cities.
Lopes PO, da Silva SR, da Silva TC, Fragoso YD, Zanesco A. Lopes PO, et al. Among authors: fragoso yd. Dement Neuropsychol. 2021 Jul-Sep;15(3):295-298. doi: 10.1590/1980-57642021dn15-030001. Dement Neuropsychol. 2021. PMID: 34630917 Free PMC article. Review.
Differential diagnosis of multiple sclerosis in Latin America.
Fragoso YD, Elso FG, Carrá A. Fragoso YD, et al. Mult Scler J Exp Transl Clin. 2017 Sep 25;3(3):2055217317714279. doi: 10.1177/2055217317714279. eCollection 2017 Jul-Sep. Mult Scler J Exp Transl Clin. 2017. PMID: 28979790 Free PMC article. Review.
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].
Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators. Fragoso YD, et al. Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. Mult Scler Relat Disord. 2018. PMID: 29807821 No abstract available.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Roos I, Diouf I, Sharmin S, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamou B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Ramo-Tello C, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sanchez-Menoyo JL, Laureys G, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Sempere AP, Trevino-Frenk I, Schepel J, Moore F, Malpas C, Kalincik T. Roos I, et al. Among authors: fragoso y. Mult Scler. 2023 Mar;29(3):326-332. doi: 10.1177/13524585231151394. Epub 2023 Feb 19. Mult Scler. 2023. PMID: 36800908
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase and OFSEP. Roos I, et al. Among authors: fragoso yd. Neurology. 2022 Oct 25;99(17):e1926-e1944. doi: 10.1212/WNL.0000000000201029. Epub 2022 Aug 17. Neurology. 2022. PMID: 35977837 Free PMC article.
210 results